Brought to you by 
ImmunoGen and Aventis develop anticancer drugs; Sanofi and ImmunoGen later amend
Aug 2003
Executive Summary
ImmunoGen's (cancer therapeutics) expertise in antibodies and Aventis's oncology product development experience will be combined in a three-year collaboration to discover, develop, and market antibody-based cancer treatments. Both partners will provide targets.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ImmunoGen and Aventis develop anticancer drugs; Sanofi and ImmunoGen later amend
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice